What the official records say about October 2026

In October 2026, 64 industry biologics trials started worldwide, 24 in the United States, 20 in Asia and 4 in Europe. In the last twelve months, only March had more worldwide, with 74. The EMA authorised 1 medicine and the FDA approved 2. The FDA also issued 14 CGMP warning letters. EU import data run to August 2026.

Europe's 4 is provisional and the lowest figure of the twelve months. Many studies reach ClinicalTrials.gov weeks after they start, so the latest month usually rises. That is what happened to September. In the October edition, with data downloaded on 1 November 2026, September had 10 trials in Europe, and the 15 November download gives it 13.

4

Biologics trials started in Europe

Previous month 13, change -9

64

Biologics trials started worldwide

Previous month 62, change +2

24

Biologics trials started in the United States

Previous month 22, change +2

20

Biologics trials started in Asia

Previous month 18, change +2

1

Medicines authorised by the EMA

Previous month 7, change -6

2

FDA approvals, CDER and CBER

Previous month 10, change -8

14

FDA CGMP warning letters

Previous month 13, change +1

See the data as a table
Indicators for October 2026 compared with September, counts of official records downloaded on 15 November 2026. October figures may still change.
IndicatorMonthPrevious monthChange
Biologics trials started in Europe

4

13

-9

Biologics trials started worldwide

64

62

+2

Biologics trials started in the United States

24

22

+2

Biologics trials started in Asia

20

18

+2

Medicines authorised by the EMA

1

7

-6

FDA approvals, CDER and CBER

2

10

-8

FDA CGMP warning letters

14

13

+1

EMA authorisations and FDA approvals from May to October 2026

In October 2026, the EMA authorised 1 human medicine through the centralised procedure, and it was not a biosimilar. The FDA approved 2, both novel drugs from CDER, while CBER approved no new licenses. Over the six months in the chart, the EMA peaks in July with 8, and the FDA in August and September with 10.

A month with 1 or 2 approvals does not signal a change of direction. The EMA authorises in batches, and the series has 14 medicines in November 2025 and only 1 in December. Recent CBER licenses may not be on the FDA page yet. And the EMA table only flags biosimilars, so it does not say whether October's medicine is a biologic.

EMA authorisations and FDA approvals to October 2026, November edition

  • EMA
  • FDA
EMA authorisations and FDA approvals to October 2026, November editionGrouped bar chart of EMA authorisations and FDA approvals by month, from 6 and 8 in May to 1 and 2 in October 2026.May 2026, EMA 66May 2026, FDA 88May 2026Jun 2026, EMA 55Jun 2026, FDA 44Jun 2026Jul 2026, EMA 88Jul 2026, FDA 88Jul 2026Aug 2026, EMA 44Aug 2026, FDA 1010Aug 2026Sep 2026, EMA 77Sep 2026, FDA 1010Sep 2026Oct 2026, EMA 11Oct 2026, FDA 22Oct 2026
EMA authorisations and FDA approvals to October 2026, November editionGrouped bar chart of EMA authorisations and FDA approvals by month, from 6 and 8 in May to 1 and 2 in October 2026.May 2026May 2026, EMA 66May 2026, FDA 88Jun 2026Jun 2026, EMA 55Jun 2026, FDA 44Jul 2026Jul 2026, EMA 88Jul 2026, FDA 88Aug 2026Aug 2026, EMA 44Aug 2026, FDA 1010Sep 2026Sep 2026, EMA 77Sep 2026, FDA 1010Oct 2026Oct 2026, EMA 11Oct 2026, FDA 22
EMA authorisations and FDA approvals to October 2026, November edition
MonthEMAFDA
May 202668
Jun 202654
Jul 202688
Aug 2026410
Sep 2026710
Oct 202612
Medicines authorised by the EMA and approved by the FDA, with CDER and CBER combined, each month from May to October 2026. Source EMA medicines table and FDA, CDER and CBER approvals

How many biologics trials started in Spain in October 2026?

ClinicalTrials.gov counts 1 industry trial with at least one biological intervention and a site in Spain, against 3 in September. The figure is provisional, from the database as of 13 November 2026, and may rise once studies that have already started are registered. A study with sites in Spain and other countries counts in each country.

Where industry biologics trials started in October 2026

By territory, the United States had 24 new trials in October 2026, Asia 20, Europe 4 and Latin America 1. The count covers industry-sponsored interventional studies with at least one biological intervention, by the start month recorded on ClinicalTrials.gov. A study with sites in several countries counts in each country and once in each territory.

In the country breakdown, Switzerland has 2, and Germany and Spain 1 each. France, Italy, the United Kingdom, the Netherlands, Belgium and Poland have none yet. The European total also includes countries outside the breakdown, and one study can count in more than one country, so the 4 do not necessarily come from those three.

For a supplier, behind each new trial is a sponsor that needs clinical trial material, often made in its own pilot plant or at a CDMO. The count understates the total, because many monoclonal antibody trials are registered as DRUG rather than BIOLOGICAL. For Europe, look at all twelve months, which range from 6 to 17 outside October.

Biologics trials started in October 2026 by territory, November edition

Biologics trials started in October 2026 by territory, November editionBar chart of industry biologics trials started in October 2026, with 24 in the United States, 20 in Asia, 4 in Europe and 1 in Latin America.EuropeEurope, 44United StatesUnited States, 2424AsiaAsia, 2020Latin AmericaLatin America, 11
Biologics trials started in October 2026 by territory, November editionBar chart of industry biologics trials started in October 2026, with 24 in the United States, 20 in Asia, 4 in Europe and 1 in Latin America.Europe4Europe, 4United States24United States, 24Asia20Asia, 20Latin America1Latin America, 1
Biologics trials started in October 2026 by territory, November edition
TerritoryTrials started
Europe4
United States24
Asia20
Latin America1
Interventional industry trials with at least one biological intervention started in October 2026, by territory, from the database as of 13 November 2026. Provisional count. Source ClinicalTrials.gov, API v2

Imports under 8419.89 into the 27 EU member states in August 2026

Eurostat publishes with a lag, and August 2026 is the latest month with data for all 27 member states, updated on 13 November. That month, the 27 imported 162,202 thousand euros under subheading 8419.89, against 194,616 in July (-16.7%). Germany imported 41,098 thousand euros, the Netherlands 15,541, France 13,476 and Spain 11,070, fourth on the list.

Subheading 8419.89 covers many machines for treating materials through a change of temperature, and bioreactors and fermenters are only part of it. It counts what enters each state from anywhere, other EU states included, in current euros. Eurostat may still revise August, and one month is not a trend.

Imports under subheading 8419.89 in August 2026, November edition

Imports under subheading 8419.89 in August 2026, November editionBar chart of imports under subheading 8419.89 in August 2026, from Germany with 41,098 thousand euros to Italy with 6,980, with Spain fourth at 11,070.GermanyGermany, 41,09841,098NetherlandsNetherlands, 15,54115,541FranceFrance, 13,47613,476SpainSpain, 11,07011,070AustriaAustria, 9,7969,796IrelandIreland, 8,4858,485HungaryHungary, 8,3938,393ItalyItaly, 6,9806,980
Imports under subheading 8419.89 in August 2026, November editionBar chart of imports under subheading 8419.89 in August 2026, from Germany with 41,098 thousand euros to Italy with 6,980, with Spain fourth at 11,070.Germany41,098Germany, 41,098Netherlands15,541Netherlands, 15,541France13,476France, 13,476Spain11,070Spain, 11,070Austria9,796Austria, 9,796Ireland8,485Ireland, 8,485Hungary8,393Hungary, 8,393Italy6,980Italy, 6,980
Imports under subheading 8419.89 in August 2026, November edition
Member stateThousand euros
Germany41,098
Netherlands15,541
France13,476
Spain11,070
Austria9,796
Ireland8,485
Hungary8,393
Italy6,980
The eight member states with the highest imports under subheading 8419.89 in August 2026, the latest month with data for all 27, in thousand euros. Source Eurostat, Comext DS-045409

Why does Europe show only 4 trials in October 2026?

Because the count is still incomplete. October is the last month in this edition and many studies are registered weeks after they start. September shows how this works, with 10 trials in Europe in the 1 November 2026 download and 13 in the 15 November one. The 4 is the lowest figure of the twelve months, but it does not yet point to a decline.

What the data show for Asia and Latin America in October 2026

In Asia, 20 biologics trials started in October 2026, and 15 of them have a site in China. South Korea has 3, Japan 2 and India 1. Latin America had 1, with a site in Colombia, while Brazil, Mexico, Argentina and Chile have none yet.

In Brazil, ANVISA registered 7 biological medicines in October and 6 in September, and the highest month in the series is April 2026, with 20. In Japan, the PMDA list has 135 new drug entries for FY2024, from April 2024 to March 2025. FY2025, still partial, has 119 entries up to February 2026.

Asia here means only Japan, China, India and South Korea, and Latin America means Brazil, Mexico, Argentina, Colombia and Chile. Studies that appear only in a national registry are left out. The ANVISA file of 13 November has no registration date, so the process completion date is used. PMDA entries include new indications and doses and serve only as context.

Do these counts measure demand for bioprocess equipment?

No. The figures are counts of official records, such as a study starting, a medicine being authorised or an FDA letter, plus the value imported under a subheading that covers far more than bioreactors. They show where the sector is moving, but they do not say how much bioprocess equipment is bought, in units or in euros. That is why there are no market sizes or forecasts here.

What a European bioprocess supplier can do with the October figures

For the coming quarter, these figures do not call for big changes. The United States, with 24 new trials, and Asia, with 20, stay within their range of the past year, so if you already sell there, keep up the effort. In Europe, check each country's twelve months in this edition's CSV file before cutting back, because the 4 is provisional. In Spain, with 1 trial in October and 3 in September, one month says little.

With trial sponsors, talk about clinical trial material, scale-up and GMP documentation. For the United States, make sure your English content answers technical questions so buyers do not need to call. For Asia, decide the language with your distributor in each country. Germany was the largest importer under subheading 8419.89 in August, but the subheading covers far more than bioreactors. If you want to sell there, it helps to have your key pages in German.

Make sure your website and datasheets state the scale each system works at and the GMP documentation that comes with it, and share them with your distributors. If you are going to a trade show before the next edition, bring these figures with their download date. crida studio does marketing for bioprocess equipment makers and life science companies, and its founder ran marketing at a European manufacturer for three and a half years.

Is your market or segment missing from this edition? Tell us which one, and we will consider adding it next month or preparing it just for you.

Suggest your market

What changed compared with September 2026

Compared with September, trials rise from 62 to 64 worldwide (+3.2%), from 22 to 24 in the United States (+9.1%) and from 18 to 20 in Asia (+11.1%). Europe goes from 13 to 4, and Latin America and Spain from 3 to 1, with October still incomplete. The September figures come from the 15 November download, and some no longer match those in the October edition.

The EMA goes from 7 authorisations to 1 and the FDA from 10 approvals to 2. CGMP warning letters rise from 13 to 14 (+7.7%), and October may still add more. Imports under subheading 8419.89 fall 16.7% from July to August. In the chart, worldwide trials range from a low of 39 in July to a high of 74 in March, and October, at 64, is the second-highest month.

Biologics trials started worldwide to October 2026, November edition

Biologics trials started worldwide to October 2026, November editionLine chart of biologics trials started worldwide each month, from 42 in November 2025 to 64 in October 2026, with a high of 74 in March and a low of 39 in July.020406080Nov 2025, 42Dec 2025, 62Jan 2026, 57Feb 2026, 56Mar 2026, 74Apr 2026, 54May 2026, 49Jun 2026, 58Jul 2026, 39Aug 2026, 44Sep 2026, 62Oct 2026, 6442743964Nov 2025Feb 2026May 2026Aug 2026Oct 2026
Biologics trials started worldwide to October 2026, November editionLine chart of biologics trials started worldwide each month, from 42 in November 2025 to 64 in October 2026, with a high of 74 in March and a low of 39 in July.Nov 2025, 42Dec 2025, 62Jan 2026, 57Feb 2026, 56Mar 2026, 74Apr 2026, 54May 2026, 49Jun 2026, 58Jul 2026, 39Aug 2026, 44Sep 2026, 62Oct 2026, 64427464Nov 2025May 2026Oct 2026
Biologics trials started worldwide to October 2026, November edition
MonthTrials
Nov 202542
Dec 202562
Jan 202657
Feb 202656
Mar 202674
Apr 202654
May 202649
Jun 202658
Jul 202639
Aug 202644
Sep 202662
Oct 202664
Interventional industry trials with at least one biological intervention started worldwide each month, November 2025 to October 2026. October is still provisional. Source ClinicalTrials.gov, API v2

Where can I download the data and how were they counted?

The figures can be downloaded as CSV and JSON from this page, with the source and download date of each value. Scripts read the eight official sources with the same filters every month, without estimates. The method section at the end of the page gives the exact query and the limits of each source.

Sources, queries and limits of this edition

All sources were downloaded on 15 November 2026. The data run to 31 October 2026, except Eurostat, which runs to August, and the PMDA list, which runs to February 2026. These are counts of official records and, for Eurostat, import values, with no estimates of our own. They do not measure orders or sales of bioprocess equipment. The latest month of each series can still move. Below are the exact query and limits for each source.

Add crida studio as a preferred source on Google